Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Other Non-Current Assets (2016 - 2025)

Heron Therapeutics' Other Non-Current Assets history spans 14 years, with the latest figure at $5.4 million for Q4 2025.

  • For Q4 2025, Other Non-Current Assets fell 16.58% year-over-year to $5.4 million; the TTM value through Dec 2025 reached $5.4 million, down 16.58%, while the annual FY2025 figure was $5.4 million, 16.58% down from the prior year.
  • Other Non-Current Assets reached $5.4 million in Q4 2025 per HRTX's latest filing, down from $5.9 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $18.0 million in Q1 2022 to a low of $346000.0 in Q1 2021.
  • Average Other Non-Current Assets over 5 years is $8.9 million, with a median of $7.4 million recorded in 2024.
  • Peak YoY movement for Other Non-Current Assets: skyrocketed 5095.66% in 2022, then plummeted 51.71% in 2023.
  • A 5-year view of Other Non-Current Assets shows it stood at $17.7 million in 2021, then decreased by 11.34% to $15.7 million in 2022, then tumbled by 48.27% to $8.1 million in 2023, then fell by 20.24% to $6.5 million in 2024, then decreased by 16.58% to $5.4 million in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Other Non-Current Assets are $5.4 million (Q4 2025), $5.9 million (Q3 2025), and $6.1 million (Q2 2025).